Valeant Completes Acquisiton of PreCision and Submits HSR Filing for Proposed Acquisition Of Allergan

Valeant Pharmaceuticals International has completed its acquisition of PreCision Dermatology, which develops and markets high-quality dermatology products, including Locoid, Hylatopic, and Clindagel.

On July 14, 2014, Valeant announced it had filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan.

On the same day, Allergan filed an investor presentation with the Securities and Exchange Commission ("SEC") and posted the presentation under the "Investors" section of the Company's website. Titled "Further Thoughts on Potential Business Risks and Issues with Valeant Pharmaceuticals International, Inc. ("Valeant"),” the presentation highlights Allergan’s concerns relating to a potential merger with Valeant, including the recent sale of filler and toxin products to Galderma and a lack of transparency in financial disclosures. The full presentation can be viewed at

More in News